These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 30703438)

  • 41. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost effectiveness of asthma controller therapies: influence of disease severity and other variables.
    Navarro RP; Parasuraman B
    Manag Care Interface; 2005 Jun; 18(6):31-40. PubMed ID: 16018297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma.
    Bever A; Dunne J; Reynolds J; Waserman S; Kaplan AG; O'Keefe A; McNeilly S; Szabo SM
    Adv Ther; 2024 Apr; 41(4):1401-1418. PubMed ID: 38349560
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of an economic model to assess the cost effectiveness of asthma management strategies.
    Price MJ; Briggs AH
    Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
    Faria R; McKenna C; Palmer S
    Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospects for new and emerging therapeutics in severe asthma: the role of biologics.
    Kepil Özdemir S; Bavbek S
    Expert Rev Respir Med; 2017 Jun; 11(6):505-512. PubMed ID: 28464704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.
    Zafari Z; Lynd LD; FitzGerald JM; Sadatsafavi M
    J Allergy Clin Immunol; 2014 Oct; 134(4):908-915.e3. PubMed ID: 24875619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Future of biologics in pediatric asthma: Optimizing response, early introduction, and equitable access to treatment.
    Schepel IRM; Banzon TM; Phipatanakul W
    Ann Allergy Asthma Immunol; 2024 Jan; 132(1):13-20. PubMed ID: 37652232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging care management strategies for severe asthma: integrating biologic therapy.
    Spjut R
    Am J Manag Care; 2022 Sep; 28(11 Suppl):S203-S209. PubMed ID: 36648385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New perspectives of childhood asthma treatment with biologics.
    Just J; Deschildre A; Lejeune S; Amat F
    Pediatr Allergy Immunol; 2019 Mar; 30(2):159-171. PubMed ID: 30444939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacoeconomic review of medical management of persistent asthma.
    Cheng JW; Arnold RJ
    Allergy Asthma Proc; 2008; 29(2):109-22. PubMed ID: 18430307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Update on Monoclonal Antibody Therapy to Treat Moderate-to-Severe Asthma: Benefits, Choices, and Limitations.
    Elliott MR; Grogan CE; Marshall GD
    Am J Med; 2023 Aug; 136(8):738-744. PubMed ID: 37210021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)].
    Milger K; Korn S; Feder C; Fuge J; Mühle A; Schütte W; Skowasch D; Timmermann H; Suhling H
    Pneumologie; 2023 Apr; 77(4):220-232. PubMed ID: 36796422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma.
    Blaiss MS; Castro M; Chipps BE; Zitt M; Panettieri RA; Foggs MB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):533-540. PubMed ID: 29103801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends and Disparities in Asthma Biologic Use in the United States.
    Inselman JW; Jeffery MM; Maddux JT; Shah ND; Rank MA
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):549-554.e1. PubMed ID: 31472294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study.
    Andersson F; Stahl E; Barnes PJ; Löfdahl CG; O'Byrne PM; Pauwels RA; Postma DS; Tattersfield AE; Ullman A;
    Respir Med; 2001 Jun; 95(6):505-12. PubMed ID: 11421509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Medication adherence in asthma therapy--a structured review].
    Fischer J; Wimmer A; Mahlich J
    Pneumologie; 2013 Jul; 67(7):406-14. PubMed ID: 23797492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review.
    Sullivan SD; Alfonso-Cristancho R; Carlson J; Mallya U; Ringold S
    J Med Econ; 2013; 16(3):391-6. PubMed ID: 23298329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.